ArticleThe Lancet. Oncology2022

Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC.

Maria Ochoa-de-Olza et al.PubMed ↗Publisher ↗

No numbers read from the abstract.